VCEL
Vericel Corporation
NASDAQ · USHealthcareBiotechnology
$45.88-1.63%
Price as of Jul 20, 2026
VCEL financials
Vericel Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $276.3M | $237.2M | $197.5M | $164.4M |
| Cost of revenue | $70.7M | $65.1M | $61.9M | $54.6M |
| Gross profit | $205.6M | $172.1M | $135.6M | $109.8M |
| Operating expenses | $194.6M | $167.6M | $142.0M | $126.8M |
| Operating income | $11.0M | $4.5M | -$6.5M | -$17.1M |
| Net income | $16.5M | $10.4M | -$3.2M | -$16.7M |
| EBITDA | $30.3M | $16.6M | $2.9M | -$11.6M |
| Basic EPS | $0.33 | $0.21 | $-0.07 | $-0.35 |
| Diluted EPS | $0.32 | $0.20 | $-0.07 | $-0.35 |
| Balance sheet | ||||
| Cash & equivalents | $100.1M | $74.5M | $69.1M | $51.1M |
| Total assets | $488.0M | $432.7M | $353.7M | $273.0M |
| Total liabilities | $133.3M | $140.8M | $127.7M | $80.7M |
| Stockholders’ equity | $354.6M | $292.0M | $226.0M | $192.3M |
| Total debt | $98.3M | $98.8M | $88.0M | $47.6M |
| Net debt | -$1.8M | $24.3M | $19.0M | -$3.5M |
| Cash flow | ||||
| Operating cash flow | $51.9M | $58.2M | $35.3M | $17.7M |
| Capital expenditure | -$27.2M | -$64.0M | -$27.5M | -$7.6M |
| Free cash flow | $24.7M | -$5.8M | $7.8M | $10.1M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |